Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 435.65% | 209.50% | 266.68% | -44.65% | -0.20% |
| Total Depreciation and Amortization | 13.18% | 10.03% | 9.76% | 12.17% | -10.95% |
| Total Amortization of Deferred Charges | 23.08% | 327.27% | -- | -- | 85.71% |
| Total Other Non-Cash Items | -2,270.12% | -2,886.49% | -2,498.05% | -46.55% | -5.21% |
| Change in Net Operating Assets | 71.36% | 129.31% | 135.04% | 91.59% | 55.88% |
| Cash from Operations | -11.83% | -17.85% | 25.51% | 5.98% | 40.77% |
| Capital Expenditure | 58.57% | 41.39% | 59.36% | 49.72% | -64.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 58.57% | 41.39% | 59.36% | 49.72% | -4,384.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 65.45% | 55.38% | 21.43% | -19.51% | -34.15% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 60.87% | 60.87% | 60.87% | -43.75% | -43.75% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 91.93% | 91.93% | 93.04% | 93.04% |
| Cash from Financing | 66.47% | 56.30% | 23.70% | 22.80% | 13.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.10% | 189.79% | 151.25% | 76.36% | 50.42% |